Related references
Note: Only part of the references are listed.Senescence-associated reprogramming promotes cancer stemness
Maja Milanovic et al.
NATURE (2018)
Regulation of senescence escape by the cdk4-EZH2-AP2M1 pathway in response to chemotherapy
Melanie Le Duff et al.
CELL DEATH & DISEASE (2018)
Cumulative defects in DNA repair pathways drive the PARP inhibitor response in high-grade serous epithelial ovarian cancer cell lines
Hubert Fleury et al.
ONCOTARGET (2017)
The senescence-associated secretory phenotype induces cellular plasticity and tissue regeneration
Birgit Ritschka et al.
GENES & DEVELOPMENT (2017)
Apoptosis is augmented in high-grade serous ovarian cancer by the combined inhibition of Bcl-2/Bcl-xL and PARP
Takuhei Yokoyama et al.
INTERNATIONAL JOURNAL OF ONCOLOGY (2017)
From basic apoptosis discoveries to advanced selective BCL-2 family inhibitors
Avi Ashkenazi et al.
NATURE REVIEWS DRUG DISCOVERY (2017)
Census and evaluation of p53 target genes
M. Fischer
ONCOGENE (2017)
Poly(ADP-ribose) polymerase activity and inhibition in cancer
Caleb Dulaney et al.
SEMINARS IN CELL & DEVELOPMENTAL BIOLOGY (2017)
Phase I, Dose-Escalation, Two-Part Trial of the PARP Inhibitor Talazoparib in Patients with Advanced Germline BRCA1/2 Mutations and Selected Sporadic Cancers
Johann de Bono et al.
CANCER DISCOVERY (2017)
Analysis of Circulating Cell-Free DnA Identifies Multiclonal Heterogeneity of BRCA2 Reversion Mutations Associated with Resistance to PARP Inhibitors
David Quigley et al.
CANCER DISCOVERY (2017)
Oncogenic senescence: a multi-functional perspective
Darren J. Baker et al.
Oncotarget (2017)
High-Throughput Functional Genetic and Compound Screens Identify Targets for Senescence Induction in Cancer
Liqin Wang et al.
CELL REPORTS (2017)
PARP Inhibitors in Reproductive System Cancers: Current Use and Developments
Geraldine O'Sullivan Coyne et al.
DRUGS (2017)
New agents that target senescent cells: the flavone, fisetin, and the BCL-XL inhibitors, A1331852 and A1155463
Yi Zhu et al.
AGING-US (2017)
Premature aging/senescence in cancer cells facing therapy: good or bad?
Llilians Calvo Gonzalez et al.
BIOGERONTOLOGY (2016)
Clearance of senescent cells by ABT263 rejuvenates aged hematopoietic stem cells in mice
Jianhui Chang et al.
NATURE MEDICINE (2016)
Identification of a novel senolytic agent, navitoclax, targeting the Bcl-2 family of anti-apoptotic factors
Yi Zhu et al.
AGING CELL (2016)
PARP inhibitor receives FDA breakthrough therapy designation in castration resistant prostate cancer: beyond germline BRCA mutations
T. Helleday
ANNALS OF ONCOLOGY (2016)
Keeping the senescence secretome under control: Molecular reins on the senescence-associated secretory phenotype
Nicolas Malaquin et al.
EXPERIMENTAL GERONTOLOGY (2016)
An Update on Poly(ADP-ribose)polymerase-1 (PARP-1) Inhibitors: Opportunities and Challenges in Cancer Therapy
Ying-Qing Wang et al.
JOURNAL OF MEDICINAL CHEMISTRY (2016)
Niraparib Maintenance Therapy in Platinum-Sensitive, Recurrent Ovarian Cancer
M. R. Mirza et al.
NEW ENGLAND JOURNAL OF MEDICINE (2016)
Radiosensitization by PARP Inhibition in DNA Repair Proficient and Deficient Tumor Cells: Proliferative Recovery in Senescent Cells
Moureq Alotaibi et al.
RADIATION RESEARCH (2016)
Laying a trap to kill cancer cells: PARP inhibitors and their mechanisms of action
Yves Pommier et al.
SCIENCE TRANSLATIONAL MEDICINE (2016)
Directed elimination of senescent cells by inhibition of BCL-W and BCL-XL
Reut Yosef et al.
NATURE COMMUNICATIONS (2016)
FDA Approval Summary: Olaparib Monotherapy in Patients with Deleterious Germline BRCA-Mutated Advanced Ovarian Cancer Treated with Three or More Lines of Chemotherapy
Geoffrey Kim et al.
CLINICAL CANCER RESEARCH (2015)
Deciphering the Insights of Poly(ADP-Ribosylation) in Tumor Progression
Maria Isabel Rodriguez et al.
MEDICINAL RESEARCH REVIEWS (2015)
Tumor suppressive effect of PARP1 and FOXO3A in gastric cancers and its clinical implications
See-Hyoung Park et al.
ONCOTARGET (2015)
DDR-mediated crosstalk between DNA-damaged cells and their microenvironment
Nicolas Malaquin et al.
FRONTIERS IN GENETICS (2015)
The fate of chemoresistance in triple negative breast cancer (TNBC)
Elma A. O'Reilly et al.
BBA CLINICAL (2015)
Sustained activation of DNA damage response in irradiated apoptosis-resistant cells induces reversible senescence associated with mTOR downregulation and expression of stem cell markers
Zhanna V. Chitikova et al.
CELL CYCLE (2014)
New Insights into PARP Inhibitors' Effect on Cell Cycle and Homology-Directed DNA Damage Repair
Petar Jelinic et al.
MOLECULAR CANCER THERAPEUTICS (2014)
A community computational challenge to predict the activity of pairs of compounds
Mukesh Bansal et al.
NATURE BIOTECHNOLOGY (2014)
CHK2 kinase in the DNA damage response and beyond
Laura Zannini et al.
JOURNAL OF MOLECULAR CELL BIOLOGY (2014)
Senescence Is a Developmental Mechanism that Contributes to Embryonic Growth and Patterning
Mekayla Storer et al.
CELL (2013)
Integrative Analysis of Complex Cancer Genomics and Clinical Profiles Using the cBioPortal
Jianjiong Gao et al.
SCIENCE SIGNALING (2013)
Derivation and characterization of matched cell lines from primary and recurrent serous ovarian cancer
Isabelle J. Letourneau et al.
BMC CANCER (2012)
Olaparib Maintenance Therapy in Platinum-Sensitive Relapsed Ovarian Cancer
Jonathan Ledermann et al.
NEW ENGLAND JOURNAL OF MEDICINE (2012)
The cBio Cancer Genomics Portal: An Open Platform for Exploring Multidimensional Cancer Genomics Data
Ethan Cerami et al.
CANCER DISCOVERY (2012)
Four faces of cellular senescence
Francis Rodier et al.
JOURNAL OF CELL BIOLOGY (2011)
DNA-SCARS: distinct nuclear structures that sustain damage-induced senescence growth arrest and inflammatory cytokine secretion
Francis Rodier et al.
JOURNAL OF CELL SCIENCE (2011)
Secondary Somatic Mutations Restoring BRCA1/2 Predict Chemotherapy Resistance in Hereditary Ovarian Carcinomas
Barbara Norquist et al.
JOURNAL OF CLINICAL ONCOLOGY (2011)
Integrated genomic analyses of ovarian carcinoma
D. Bell et al.
NATURE (2011)
Characterization of human breast cancer cell lines for the studies on p53 in chemical carcinogenesis
Marjo Huovinen et al.
TOXICOLOGY IN VITRO (2011)
The Senescence-Associated Secretory Phenotype: The Dark Side of Tumor Suppression
Jean -Philippe Coppe et al.
ANNUAL REVIEW OF PATHOLOGY-MECHANISMS OF DISEASE (2010)
Drug Combination Studies and Their Synergy Quantification Using the Chou-Talalay Method
Ting-Chao Chou
CANCER RESEARCH (2010)
A Versatile Viral System for Expression and Depletion of Proteins in Mammalian Cells
Eric Campeau et al.
PLOS ONE (2009)
Characterization of three new serous epithelial ovarian cancer cell lines
Veronique Ouellet et al.
BMC CANCER (2008)
Senescence-Associated Secretory Phenotypes Reveal Cell-Nonautonomous Functions of Oncogenic RAS and the p53 Tumor Suppressor
Jean-Philippe Coppe et al.
PLOS BIOLOGY (2008)
Failure of stress-induced downregulation of Bcl-2 contributes to apoptosis resistance in senescent human diploid fibroblasts
S. J. Ryu et al.
CELL DEATH AND DIFFERENTIATION (2007)
p53-independent regulation of p21Waf1/Cip1 expression and senescence by Chk2
CM Aliouat-Denis et al.
MOLECULAR CANCER RESEARCH (2005)
Integration of Smad and Forkhead pathways in the control of neuroepithelial and glioblastoma cell proliferation
J Seoane et al.
CELL (2004)
Reversal of human cellular senescence:: roles of the p53 and p16 pathways
CM Beauséjour et al.
EMBO JOURNAL (2003)
Share Paper
